as it would essentially let the cancer cells kill themselves. Scientists working in a lab. Image source: chokniti / Adobe One of the main proteins used in the new procedure is called BCL6 ...

Research uncovers how P-stalk ribosomes regulate cytokine responses, driving immune evasion in tumors across multiple cancer ...

The new compound would have to bind two proteins which already exist in the cancerous cells, turning apoptosis back on and making the cancer kill itself. "We essentially want to have the same kind ...

South San Francisco, California Saturday, October 26, 2024, 18:00 Hrs [IST] ...

Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate; ...

Lyell Immunopharma (LYEL) announced that it has entered into a definitive agreement to acquire ImmPACT Bio, a privately-owned clinical-stage ...

In addition, Imugene has made strides in expanding its trial. The Cohort Review Committee has cleared the first cohort of ...

Purple Biotech (PPBT) announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European ...